: P% h3 |0 u. l* M6 VCSL公司研究部副总裁Andrew Nash博士赞同，这一研究确定了interleukin-11在胃癌和肠癌中的潜在重要作用。“我们已经开发了大量靶向interleukin-11受体的潜在候选药物，这一数据提供了临床前数据支持进入到临床研究中，”Nash博士说。 ' }) X; i6 _! S) r + B$ \5 _/ D4 ^7 B' B（生物通：何嫱） 7 L4 S3 W t, H% j0 ~2 f2 \1 |% @0 \) I9 ~; u
( n+ v0 u/ j$ C6 N4 ?' {6 T! B4 e6 a, f
1 M8 ^4 m4 o; \9 u3 b' ^3 c/ ^& K
Interleukin-11 Is the Dominant IL-6 Family Cytokine during Gastrointestinal Tumorigenesis and Can Be Targeted Therapeutically3 x* Q7 ]8 i; b1 o- p) c; Z+ G
" p5 x* E _3 V. ]: {( ? q4 n
Among the cytokines linked to inflammation-associated cancer, interleukin (IL)-6 drives many of the cancer hallmarks through downstream activation of the gp130/STAT3 signaling pathway. However, we show that the related cytokine IL-11 has a stronger correlation with elevated STAT3 activation in human gastrointestinal cancers. Using genetic mouse models, we reveal that IL-11 has a more prominent role compared to IL-6 during the progression of sporadic and inflammation-associated colon and gastric cancers. Accordingly, in these models and in human tumor cell line xenograft models, pharmacologic inhibition of IL-11 signaling alleviated STAT3 activation, suppressed tumor cell proliferation, and reduced the invasive capacity and growth of tumors. Our results identify IL-11 signaling as a potential therapeutic target for the treatment of gastrointestinal cancers.作者: biobio 时间: 2015-5-21 16:34